Uscom Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Sydney, NSW Australia
Total Funding:N/A
Industry:Medical Equip
Founded:1999
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Uscom's estimated annual revenue is currently $11.5M per year.(?)
  • Uscom's estimated revenue per employee is $251,000

Employee Data

  • Uscom has 46 Employees.(?)
  • Uscom grew their employee count by 15% last year.
  • Uscom currently has 1 job openings.

ASX: UCM Uscom specialises in the development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring. The USCOM 1A is a cost-effective and non-invasive advanced hemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A has major applications in Pediatrics, Emergency, Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and pediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy. The Uscom BP+ is a supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ is the emerging standard of care measurement in hypertension, heart failure and vascular health. It provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. Uscom SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance.

keywords:N/A